REGENXBIO INC. DL-,0001 WKN: A140E0 ISIN: US75901B1070 Kürzel: RB0 Forum: Aktien Thema: Hauptdiskussion

REGENXBIO Announces Dosing of First Patient in Cohort 3 of Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) https://www.prnewswire.com/news-releases/regenxbio-announces-dosing-of-first-patient-in-cohort-3-of-phase-iii-trial-of-rgx-121-for-the-treatment-of-mps-ii-hunter-syndrome-301269209.html • First patient dosed at third dose level in ongoing trial of RGX-121, a one-time gene therapy for MPS II; total of nine patients have been dosed at four leading clinical centers in the U.S. and Brazil  • Previously reported positive interim data from Cohorts 1 and 2 demonstrated consistent reductions in CNS biomarkers, continued neurocognitive development, and evidence of systemic effects ...

Regenxbio: 4Q Earnings Snapshot https://www.sfchronicle.com/business/article/Regenxbio-4Q-Earnings-Snapshot-15990371.php REGENXBIO Reports Fourth Quarter and Full-Year 2020 Financial Results and Operational Highlights https://www.prnewswire.com/news-releases/regenxbio-reports-fourth-quarter-and-full-year-2020-financial-results-and-operational-highlights-301237754.html

REGENXBIO Announces Additional Positive Interim Phase I/IIa and Long-Term Follow-Up Data of RGX-314 for the Treatment of Wet AMD https://www.prnewswire.com/news-releases/regenxbio-announces-additional-positive-interim-phase-iiia-and-long-term-follow-up-data-of-rgx-314-for-the-treatment-of-wet-amd-301228344.html ...

REGENXBIO patent case may weigh on Sarepta, according to Morgan Stanley https://seekingalpha.com/news/3660139-regenxbio-patent-case-may-weigh-on-sarepta-according-to-morgan-stanley • Morgan Stanley analyst Matthew Harrison writes that a patent case filed by REGENXBIO Inc. (NASDAQ:RGNX) against Sarepta Therapeutics (NASDAQ:SRPT) regarding SRP-9001 and SRP-9003 could have implications for the company. • In late December, a federal judge denied a motion from Sarepta Therpeutics (SRPT) to dismiss a lawsuit filed by Wilson Wolf Manufacturing Corp. regarding SRP-9001. • Harrison notes that REGENEXBIO "may be able to obtain a higher royalty based on its AAV patent (a mid-to-high single-digit royalty) than Wilson Wolf can likely obtain based on its cell-culture-device patent (a low single-digit royalty)." • Sarepta has also filed a motion to dismiss the REGENXBIO case. • Harrison maintains an equal-weight rating on the stock and a $95 price target.

🎯

https://www.wfmz.com/news/pr_newswire/pr_newswire_business/regenxbio-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option/article_face8711-b686-5c26-b70e-60d65205afa4.html

REGENXBIO Announces Proposed Public Offering Of Common Stock https://www.prnewswire.com/news-releases/regenxbio-announces-proposed-public-offering-of-common-stock-301202287.html

REGENXBIO Announces Update on RGX-314 and Pivotal Program for the Treatment of Wet AMD and New Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy https://www.prnewswire.com/news-releases/regenxbio-announces-update-on-rgx-314-and-pivotal-program-for-the-treatment-of-wet-amd-and-new-gene-therapy-program-for-the-treatment-of-duchenne-muscular-dystrophy-301201378.html

REGENXBIO Announces Agreement to Monetize Portion of Zolgensma Royalties for $200 Million https://www.prnewswire.com/news-releases/regenxbio-announces-agreement-to-monetize-portion-of-zolgensma-royalties-for-200-million-301197818.html Agreement with Healthcare Royalty enables REGENXBIO to advance its broad gene therapy pipeline, including pivotal program for RGX-314 ...

Regenxbio: Championing Gene Therapy https://seekingalpha.com/article/4395464-regenxbio-championing-gene-therapy

https://www.prnewswire.com/news-releases/regenxbio-announces-dosing-of-first-patient-in-phase-ii-altitude-trial-of-rgx-314-for-the-treatment-of-diabetic-retinopathy-using-suprachoroidal-delivery-301190019.html

REGENXBIO Announces Positive Interim Data and Update for Phase I/II Trial of RGX-121 for the Treatment of MPS II https://www.prnewswire.com/news-releases/regenxbio-announces-positive-interim-data-and-update-for-phase-iii-trial-of-rgx-121-for-the-treatment-of-mps-ii-301189001.html - Consistent reductions in CSF levels of heparan sulfate up to 2 years after administration, as well as continued developmental skill acquisition - Initial data from Cohort 2 indicates evidence of systemic enzyme expression and biomarker activity - Additional data from Cohorts 1 and 2 to be presented at WORLDSymposium in February 2021 - REGENXBIO expects to initiate dosing of patients in Cohort 3 at an increased dose in the first quarter of 2021 ...

Regenxbio EPS beats by $1.14, beats on revenue https://seekingalpha.com/news/3631476-regenxbio-eps-beats-1_14-beats-on-revenue Regenxbio (NASDAQ:RGNX): Q3 GAAP EPS of $0.24 beats by $1.14. Revenue of $98.9M (+572.8% Y/Y) beats by $74.1M.

REGENXBIO Announces Continued Progress and Expansion of Clinical Development Program for RGX-121 for the Treatment of Mucopolysaccharidosis Type II (MPS II) https://www.prnewswire.com/news-releases/regenxbio-announces-continued-progress-and-expansion-of-clinical-development-program-for-rgx-121-for-the-treatment-of-mucopolysaccharidosis-type-ii-mps-ii-301141550.html

https://dc.citybizlist.com/article/628211/regenxbio-more-robust-data-for-wet-amd Regenxbio: More Robust Data For Wet AMD

https://seekingalpha.com/article/4373916-regenxbio-robust-data-for-wet-amd